Atea Pharmaceuticals to join the Nasdaq Biotechnology Index

- Advertisement - (adsbygoogle = window.adsbygoogle || []).push({});

a clinical-stage biopharmaceutical business specializing in creating, manufacturing, and marketing oral treatments for patients suffering life-threatening viral infections.

Jean Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, expressed delight over the recognition. He said, “We are pleased to join the NASDAQ Biotechnology Index as it heightens and expands our profile within the investment community. Inclusion in the index broadens awareness of Atea and its mission to develop safe and effective oral antiviral treatments that address unmet medical needs of patients with life-threatening viral diseases, including COVID-19.”

kun.uz

The NASDAQ Biotechnology Index is designed to monitor the performance of a diversified portfolio of businesses traded on The Nasdaq Stock Market® (Nasdaq®) that are categorized as biotechnology or pharmaceutical based on the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index utilizes a modified capitalization-weighted approach to calculate its value. Companies eligible for inclusion in the NASDAQ Biotechnology Index must fulfill a number of criteria, such as a minimum market capitalization, an average daily trading volume, and duration as a publicly traded business. Each year in December, Nasdaq chooses eligible businesses.

Using the firm’s deep expertise in antiviral medication development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has developed a patented nucleotide prodrug platform to develop innovative pharmaceutical candidates for treating single stranded ribonucleic acid, or ssRNA, viruses, which frequently cause serious viral infections. Atea is now working on the development of orally available, potent, and selective nucleotide prodrugs for the treatment of difficult-to-treat, harmful viral diseases, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV), and respiratory syncytial virus (RSV).

A Personal Note from the Publisher" Small photo of you, with your signature beneath

A Personal Note from the Publisher

My dear friend, thank you for your time with us today. This site was built for you, the members of the Commonwealth Family, and nothing matters more to me than hearing your voice and feedback.

What did you make of this article? Did it inform you, challenge you, or leave you wanting more?

Please tell me. I read your replies personally and they help shape everything we publish.

With warmest wishes,
Hon. Nirj Deva
Founder and Publisher.

Free, always. We'll never sell your details.

spot_img

Hot this week

India’s Gold Revolution: You Can Now Own Gold Without Ever Holding It—What Is Changing?

MUMBAI, INDIA — 20 NOVEMBER 2026 People in India have...

Malta’s New Tourist Tax Set to Exceed Rates in Competing Mediterranean Destinations

Travellers planning a holiday in Malta will soon face...

TSMC Tightens Chip Manufacturing Rules for Chinese Companies After New US Export Controls

The world’s largest contract chipmaker, Taiwan Semiconductor Manufacturing Co...

Jamaica and the United States Sign Customs Agreement to Bolster Border Security

Jamaica and the United States have signed a new...

The Flight Was Over, But the Danger Wasn’t: Why Two Virgin Australia Pilots Refused to Fly Again

ADELAIDE, AUSTRALIA — 20 NOVEMBER 2026 It is possible for...
- Advertisement - (adsbygoogle = window.adsbygoogle || []).push({});

Related Articles

- Advertisement -sitaramatravels.comsitaramatravels.com

Popular Categories